Nov 8 (Reuters) - Allovir Inc :
* ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF THE RETINA
* ALLOVIR INC - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST
* ALLOVIR INC - STOCKHOLDERS TO OWN 25.05% OF COMBINED COMPANY POST-MERGER
* ALLOVIR INC - COMBINED COMPANY TO BE LED BY KALARIS CEO ANDREW OXTOBY
* ALLOVIR INC - COMBINED COMPANY TO OPERATE AS KALARIS THERAPEUTICS, INC. AND TRADE AS KLRS
* ALLOVIR INC - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED IN Q3 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。